# Transcorneal Bio-Transport
### A Computational Model of Ophthalmic Drug Diffusion

**Python | Numerical Methods | Partial Differential Equations | Computational Ophthalmology**

## Overview

Transcorneal Bio-Transport is a computational research project exploring how ophthalmic drug molecules diffuse through an idealised corneal tissue model over time.

The project uses a finite-difference numerical method to approximate a one-dimensional diffusion–reaction partial differential equation.

Its purpose is to demonstrate the application of mathematical modelling, numerical analysis, and scientific programming to ophthalmology.

**Research question:** How do diffusion coefficients, corneal thickness, and first-order loss rates influence simulated drug concentration profiles?

## 1. Mathematical Model

The model is governed by:

\[
\frac{\partial C}{\partial t}
=
D\frac{\partial^2 C}{\partial x^2}-k_{el}C
\]

Where:

- \(C(x,t)\) is the local drug concentration.
- \(D\) is the effective diffusion coefficient (cm²/s).
- \(x\) is the position across the cornea (cm).
- \(t\) is time (seconds).
- \(k_{el}\) is an effective first-order loss coefficient (s⁻¹).

### Baseline parameters

| Parameter | Value | Unit |
|---|---:|---|
| Corneal thickness, L | 0.05 | cm |
| Diffusion coefficient, D | 3.2 × 10⁻⁶ | cm²/s |
| Effective loss coefficient, k_el | 1.5 × 10⁻⁴ | s⁻¹ |
| Normalised surface concentration | 1.0 | Arbitrary units |

These are illustrative modelling parameters, not experimentally validated values for a particular ophthalmic drug.

## 2. Initial and Boundary Conditions

The initial concentration within the cornea is assumed to be zero:

\[
C(x,0)=0,\quad 0<x\leq L
\]

The anterior surface is represented by a constant-concentration reservoir:

\[
C(0,t)=C_0
\]

The posterior boundary is represented by a zero-flux condition:

\[
\left.\frac{\partial C}{\partial x}\right|_{x=L}=0
\]

These boundary conditions are mathematical simplifications.

In particular, the zero-flux posterior boundary prevents drug transport into the aqueous humour. Therefore, the current model cannot predict actual aqueous-humour drug delivery or bioavailability.

## 3. Numerical Method

The governing equation is approximated using the forward-time, centred-space finite-difference method:

\[
C_i^{n+1}
=
C_i^n
+
\frac{D\Delta t}{(\Delta x)^2}
(C_{i+1}^n-2C_i^n+C_{i-1}^n)
-k_{el}\Delta t C_i^n
\]

For this explicit scheme, the time step must be selected to satisfy an appropriate stability condition.

For the non-negative diffusion–reaction discretisation used here:

\[
\Delta t\leq
\frac{1}{2D/(\Delta x)^2+k_{el}}
\]

## 4. Research Outputs

The simulation is designed to produce:

- Drug concentration profiles across corneal depth.
- Concentration heatmaps over time.
- Posterior-surface concentration curves.
- Sensitivity analysis for diffusion and loss parameters.
- Numerical stability and convergence checks.

## 5. Scientific Limitations

This is an idealised, one-dimensional, homogeneous tissue model.

It does not explicitly represent the epithelial, stromal, and endothelial layers as separate compartments. It also omits tear-film turnover, drug partition coefficients, binding kinetics, aqueous-humour transport, and patient-specific variation.

The results should not be interpreted as clinical predictions, treatment recommendations, or validated pharmacokinetic estimates.

## 6. Future Research Directions

1. Implement a three-layer corneal diffusion model.
2. Introduce tissue-specific diffusion coefficients.
3. Model finite-dose tear-film clearance.
4. Add a posterior permeability boundary.
5. Compare numerical solutions with analytical benchmarks.
6. Perform mesh-convergence and parameter-sensitivity studies.
7. Compare simulations against published experimental data.

## 7. Reproducibility

The repository should include the Python simulation, dependency requirements, automated numerical tests, and instructions for reproducing each figure.

## Disclaimer

This software is intended exclusively for educational and computational research purposes. It is not a medical device and has not been validated for clinical decision-making.
